Tags : Rights

Merck Animal Health to Acquire Rights to Sentinel Brand of

Shots: Merck Animal Health to acquire the US rights to Sentinel flavor tabs and chews in the companion animal category, under the agreement with Virbac. The transaction is expected to be closed by mid-2020 With the acquisition, Merck expects to provide veterinarians continuous parasite protection for dogs in easy to administer, palatable formulations The products […]Read More

Collegium to Acquire US Rights of Assertio’s Nucynta Franchise for

Shots: Assertio to receive $375M upfront in cash and fewer royalties in 2020, subject to certain adjustments. Collegium to get the US license or the Nucynta Franchise and will not pay royalties to Assertio with the anticipated completion of the transaction on Feb 14, 2020 Additionally, Collegium will continue to pay 14% royalties on net […]Read More

AstraZeneca Divests Rights of Seroquel and Seroquel XR to Cheplapharm

Shots: AstraZeneca to receive $178M up front and up to $61M as sales-contingent payments while it continues to manufacture and supply Seroquel and Seroquel XR to Cheplapharm during a transition period. The transaction is expected to be closed in Q4’19 The divestiture will allow AstraZeneca to focus on its main therapeutic areas by reducing its […]Read More

Reata Regains Exclusive Worldwide Rights of its Nrf2 Activator Product

Shots: AbbVie to receive $330M in cash primarily for bardoxolone, $75M up front in 2019 and the remaining value payable in installments in Q2 and Q4 2020 plus royalties on WW sales of omaveloxolone and certain next-generation Nrf2 activators Reata reacquires WW rights to develop, manufacture and commercialize bardoxolone methyl (ex- Asian markets), omaveloxolone and […]Read More

Daiichi Sankyo to Return Exclusive Development and Commercialization Rights for

Shots: Daiichi to return rights for four diagnostic imaging agents to GE Healthcare Omnipaque, Omniscan, including Visipaque, Sonazoid and the transfer of marketing authorization rights is expected to be complete in Mar’2020 GE Healthcare will be responsible for commercialization & regulatory activities for all four imaging agents. Daiichi will hold the rights to distribute the […]Read More